Meeting
2018 ASCO Annual Meeting
Plasma and tumor genomic correlates of response to BYL719 in PI3KCA mutated metastatic ER-positive breast cancer (ER+/HER2- BC).
Authors
Sarah-Jane Dawson
Peter MacCallum Cancer Centre, Melbourne, Australia
Sarah-Jane Dawson , Lironne Wein , Maria Joao Silva , Stephen James Luen , Courtney VanGeelen , Kate Moodie , Peter Savas , Chen-Fang Weng , Andjelija Zivanovic Bujak , Miriam M Yeung , Sarah Ftouni , Keilly Kuykhoven , Rodney J Hicks , Prudence A. Francis , Chee Khoon Lee , Sherene Loi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02506556
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1055)
DOI
10.1200/JCO.2018.36.15_suppl.1055
Abstract #
1055
Poster Bd #
136
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.
First Author: Werner J. Struss
Poster
2016 ASCO Annual Meeting
A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer.
First Author: Nikhil Wagle
Poster
2015 ASCO Annual Meeting
Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway.
First Author: Esther P. Black
Poster
2023 ASCO Annual Meeting
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
First Author: Arielle J Medford